Aprea Therapeutics Q3 2026 Results: Net Loss of $4.81M, Loss Widens
Aprea Therapeutics reported a net loss of $11.7 million for the nine months ended September 30, 2026, compared to a $10.1 million loss in the prior year period, driven primarily by increased research and development expenses. The company significantly strengthened its liquidity, ending the period with $37.8 million in cash and cash equivalents following equity financing activities.
- Key figure
- Net loss $4.81M